- Full Year 2024 Terumo Corp Earnings Presentation TranscriptMay 14, 2024
- Q3 2024 Terumo Corp Earnings Presentation TranscriptFeb 07, 2024
- Q2 2024 Terumo Corp Earnings Presentation TranscriptNov 14, 2023
- Q1 2024 Terumo Corp Earnings Presentation TranscriptAug 09, 2023
- Full Year 2023 Terumo Corp Earnings Call TranscriptMay 15, 2023€14.2 (+0.71%)Earnings
- Q3 2023 Terumo Corp Earnings Call TranscriptFeb 09, 2023€13.3 (-1.48%)Earnings
- Q2 2023 Terumo Corp Earnings Call TranscriptNov 10, 2022€14.7 (-0.68%)Earnings
- Q1 2023 Terumo Corp Earnings Call TranscriptAug 09, 2022€15.4 (-3.75%)Earnings
- Full Year 2022 Terumo Corp Earnings Call TranscriptMay 12, 2022€13.6 (-2.86%)Earnings
- Q3 2022 Terumo Corp Earnings Call TranscriptFeb 09, 2022€15.75 (+3.06%)Earnings
- Terumo Corp New Growth Strategy Briefing TranscriptDec 16, 2021
- Q2 2022 Terumo Corp Earnings Call TranscriptNov 04, 2021€19.5 (+2.63%)Earnings
- Q1 2022 Terumo Corp Earnings Call TranscriptAug 04, 2021€16.3 (-1.21%)Earnings
- Full Year 2021 Terumo Corp Earnings Call TranscriptMay 12, 2021€15.2 (-1.30%)Earnings
- Q3 2021 Terumo Corp Earnings Call TranscriptFeb 04, 2021€17.1 (+4.27%)Earnings
- Q2 2021 Terumo Corp Earnings Call TranscriptNov 05, 2020€16 (+0.63%)Earnings
- Q1 2021 Terumo Corp Earnings Call TranscriptAug 06, 2020€15.9 (-1.24%)Earnings
- Full Year 2020 Terumo Corp Earnings Call TranscriptMay 18, 2020€16.6 (+7.79%)Earnings
- Q3 2020 Terumo Corp Earnings Call TranscriptFeb 06, 2020€16.6 (+2.47%)Earnings
- Q2 2020 Terumo Corp Earnings Presentation TranscriptNov 07, 2019
- Q1 2020 Terumo Corp Earnings Call TranscriptAug 08, 2019€13.21 (+2.88%)Earnings
- Full Year 2019 Terumo Corp Earnings Presentation TranscriptMay 09, 2019
Q3 2022 Terumo Corp Earnings Call Transcript
I am the CFO, Muto. I will now explain the third quarter results for the fiscal year ending March 2022. First, the highlights from the quarter.
Q3 stand-alone revenue grew 8% from the previous year. Year-to-date revenue also grew 17%. The Cardiac and Vascular Company entered a COVID-19 recovery pattern, growing 12% from the previous year, with strong demand. Blood and Cell Technologies Company grew the next most.
Adjusted operating profits slowed slightly in the third quarter amid continued production adjustment to normalize inventory down from COVID safety stock levels as well as impact from higher freight and raw materials costs caused by global supply chain disruption.
Year-to-date profit grew 21% from the previous year. In light of these third quarter results, we will revise the annual guidance for revenue only upward by JPY 12 billion. Although we anticipate a temporary Q4 decrease in health care demand due to COVID omicron variant's impact, we decided to account for Q3
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)